Abstract: The present disclosure provides for suspension-based pharmaceutical formulations for cold and flu medications, specifically suspension formulations and soft gel capsule dosage forms having reduced size. The present disclosure also provides methods of preparing the suspensions and soft gel capsule dosage forms.

Abstract: Provided are non-breathable films including specific polymer blends, and methods for making such films. The films comprise an anhydride and/or carboxylic acid functionalized ethylene/alpha-olefin interpolymer, a linear low density polyethylene, and an inorganic filler. The method of manufacturing the film comprises extruding an anhydride and/or carboxylic acid functionalized ethylene/alpha-olefin interpolymer, a linear low density polyethylene, and an inorganic filler to form the film and stretching the film. The films according to embodiments disclosed herein can exhibit low WVTR values and improved modulus while also incorporating significant amounts of inorganic filler at low gauges.

Abstract: A method for producing a welded blank (1) includes providing two precoated sheets (2), butt welding the precoated sheets (2) using a filler wire. The precoating (5) entirely covers at least one face (4) of each sheet (2) at the time of butt welding. The filler wire (20) has a carbon content between 0.01 wt. % and 0.45 wt. %. The composition of the filler wire (20) and the proportion of filler wire (20) added to the weld pool is chosen such that the weld joint (22) has (a) a quenching factor FTWJ: FTWJ?0.9FTBM?0, where FTBM is a quenching factor of the least hardenable substrate (3), and FTWJ and FTBM are determined: FT=128+1553×C+55×Mn+267×Si+49×Ni+5×Cr?79×Al?2×Ni2?1532×C2?5×Mn2?127×Si2?40×C×Ni?4×Ni×Mn, and (b) a carbon content CWJ<0.15 wt. % or, if CWJ?0.15 wt. %, a softening factor FAWJ such that FAWJ>5000, where FA=10291+4384.1×Mo+3676.9Si?522.64×Al?2221.2×Cr?118.11×Ni?1565.1×C?246.67×Mn.

Abstract: The present disclosure provides for suspension-based pharmaceutical formulations for cold and flu medications, specifically suspension formulations and soft gel capsule dosage forms having reduced size. The present disclosure also provides methods of preparing the suspensions and soft gel capsule dosage forms.

Abstract: The present disclosure relates to compositions, including foamable compositions with improved properties, such as those comprising waxes, emollients, foam adjuvants and/or active agents, and methods for preparing and using them.

Abstract: Virtual Network Functions (VNF) applies automation and virtualization techniques to move current network functions from dedicated hardware to general purpose hardware of an Information Technology (IT) infrastructure. A VNF may include one or more Virtual Machines (VM) and virtual networks which may implement the function of a network. Systems and methods provide a processing unit, a computation module and an allocation module for VNF allocation. The computation module is configured to determine an extinction factor corresponding to a datacenter unit based on a state of the datacenter and a VNF catalogue including a plurality of VNFs. The computation module is also configured to develop an allocation model based on the determined extinction factor. The allocation module is configured to allocate a first VNF from the plurality of VNFs in the datacenter based on the allocation model.

Abstract: Biopesticide and biofertilizer composition comprising Pseudoxanthomonas indica, or metabolites from said bacterium, and excipients or diluents. Use of Pseudoxanthomonas indica, or metabolites from said bacterium to develop a biopesticide or biofertilizer composition. Method for the control of phytopathogens and zoonematodes comprising the administration of an effective amount of Pseudoxanthomonas indica, or its metabolites, to the plant or animal in need thereof. Method for the stimulation of plant growth comprising the administration of an effective amount of Pseudoxanthomonas indica, or metabolites from that bacterium, to the soil or substrate, plant or seed.

Abstract: An example computing system for allocating Virtual Network Functions (VNF) in a datacenter is disclosed. The example disclosed herein comprises a processing unit, a computation module and an allocation module. The computation module is configured to determine an extinction factor corresponding to a datacenter unit in the datacenter based on a state of the datacenter and a VNF catalogue including a plurality of VNFs; and to develop an allocation model based on the determined extinction factor. The allocation module is configured to allocate a first VNF from the plurality of VNFs in the datacenter based on the allocation model.

Abstract: A rubber composition, comprising i) an ethylene-?-olefin-non-conjugated-diene copolymer having—a Mooney viscosity ML (1+8) at 150° C.?85 MU and—an ethylene content ?63 wt. %—the diene content is 4 to 8% by weight of the ethylene-a-olefin-non-conjugated-diene copolymer i), —the non-conjugated diene is a combination of 5-ethylidene-2-norbornene (ENB) and 5-vinylnorbornene (VNB), —the ethylene-?-olefin-non-conjugated-diene copolymer i) has an amount of VNB between 0.05 and 1 wt. %, and has a Mw of at least 400,000 g/mol and, ii) an extender oil of 10 to 40 phr based on the copolymer i) with the sum of the EPDM copolymer i) and the oil ii) amounting to at least 95 wt. % of the composition.

Abstract: An example computing system for allocating Virtual Network Functions (VNF) in a datacenter includes a processing unit, a computation module and an allocation module. The computation module is configured to determine an extinction factor corresponding to a datacenter unit in the datacenter based on a state of the datacenter and a VNF catalogue including a plurality of VNFs; and to develop an allocation model based on the determined extinction factor. The allocation module is configured to allocate a first VNF from the plurality of VNFs in the datacenter based on the allocation model.

Abstract: A bakery cart includes a frame and a top cover. The frame includes corner supports, base rails, shelf ledges and hinged beams. The top cover swings from a cover position to a stow position, and frame moves from an expanded position to a collapsed position to reduce the frame width. Advantageously, the bakery cart is a reliable, lightweight, collapsible cart with a simple, inexpensive construction for holding shelves with food products in the expanded position and compact storage in the collapsed position.

Abstract: The invention provides a composition rich in flavonoids based on natural extracts, comprising a flavonoid extract dispersed by melt mixing or extrusion and encapsulated in a polymer matrix. The invention is also a novel dietary supplement with the naturally occurring ingredient (?)-epicatechin, cacao extracted, that could potentially prevent or reduce the risk of Atherosclerotic pathology. The use of (?)-epicatechin is promising as a therapeutic agent due to its potential antioxidant activity and its diverse biological properties. (?)-Epicatechins are chemically unstable and extensively degraded in fluids of near neutral or greater pH, such as intestinal juice and bile. Current technologies used for taste masking and modified release as spray drying, liposome entrapment, co-crystallization, freeze drying, among others, suffer from numerous shortcomings, including poor repeatability and limitations on target delivery.

Abstract: The invention provides a composition rich in flavonoids based on natural extracts, comprising a flavonoid extract dispersed by melt mixing or extrusion and encapsulated in a polymer matrix. The invention is also a novel dietary supplement with the naturally occurring ingredient (?)-epicatechin, cacao extracted, that could potentially prevent or reduce the risk of Atherosclerotic pathology. The use of (?)-epicatechin is promising as a therapeutic agent due to its potential antioxidant activity and its diverse biological properties. (?)-Epicatechins are chemically unstable and extensively degraded in fluids of near neutral or greater pH, such as intestinal juice and bile. Current technologies used for taste masking and modified release as spray drying, liposome entrapment, co-crystallization, freeze drying, among others, suffer from numerous shortcomings, including poor repeatability and limitations on target delivery.

Abstract: A rubber composition, comprising i) an ethylene-?-olefin-non-conjugated-diene copolymer having—a Mooney viscosity ML (1+8) at 150 ° C. ?85 MU and—an ethylene content?63 wt. %—the diene content is 4 to 8% by weight of the ethylene-a-olefin-non-conjugated-diene copolymer i), —the non-conjugated diene is a combination of 5-ethylidene-2-norbornene (ENB) and 5-vinylnorbornene (VNB), —the ethylene-?-olefin-non-conjugated-diene copolymer i) has an amount of VNB between 0.05 and 1 wt. %, and has a Mw of at least 400,000 g/mol and, ii) an extender oil of 10 to 40 phr based on the copolymer i) with the sum of the EPDM copolymer i) and the oil ii) amounting to at least 95 wt. % of the composition.

Abstract: An example computing system for allocating Virtual Network Functions (VNF) in a datacenter is disclosed. The example disclosed herein comprises a processing unit, a computation module and an allocation module. The computation module is configured to determine an extinction factor corresponding to a datacenter unit in the datacenter based on a state of the datacenter and a VNF catalogue including a plurality of VNFs; and to develop an allocation model based on the determined extinction factor. The allocation module is configured to allocate a first VNF from the plurality of VNFs in the datacenter based on the allocation model.

Abstract: The invention provides a composition rich in flavonoids based on natural extracts, comprising a flavonoid extract dispersed by melt mixing or extrusion and encapsulated in a polymer matrix. The invention is also a novel dietary supplement with the naturally occurring ingredient (?)-epicatechin, cacao extracted, that could potentially prevent or reduce the risk of Atherosclerotic pathology. The use of (?)-epicatechin is promising as a therapeutic agent due to its potential antioxidant activity and its diverse biological properties. (?)-Epicatechins are chemically unstable and extensively degraded in fluids of near neutral or greater pH, such as intestinal juice and bile. Current technologies used for taste masking and modified release as spray drying, liposome entrapment, co-crystallization, freeze drying, among others, suffer from numerous shortcomings, including poor repeatability and limitations on target delivery.

Abstract: There is provided compounds of formula I, wherein R1, R2a, R2b, R2c, X, Y, Z, R3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.

Abstract: There is provided compounds of formula I, wherein R1, R2a, R2b, R2c, X, Y, Z, R3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.

Abstract: There is provided compounds of formula I, wherein R1, R2a, R2b, R2c, X, Y, Z, R3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.

Abstract: There is provided compounds of formula (I), wherein A1, A4, A4a, A5, B1, B1a, B2, B2a, B3, B3a, B4, B4a and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.